Tags

Type your tag names separated by a space and hit enter

Hormone-replacement therapy increases serum paraoxonase arylesterase activity in diabetic postmenopausal women.
Metabolism. 2001 Mar; 50(3):319-24.M

Abstract

The paraoxonase (PON1) enzyme is associated with high-density lipoproteins (HDL) in the blood and is low in patients with type 2 diabetes. Hormone-replacement therapy (HRT) can increase HDL cholesterol levels, but its effect on serum PON1 arylesterase activity is uncertain. The aim of the present study was to determine the effect of 6 months' HRT with conjugated equine estrogen and medroxyprogesterone acetate on serum PON1 arylesterase activity in postmenopausal women with type 2 diabetes. Serum PON1 activity was measured immediately before and at the end of the second arm of a randomized, placebo-controlled, crossover with washout study originally designed to test the effect of HRT on plasma lipids in diabetic postmenopausal women. Baseline serum PON1 arylesterase activity was significantly (P <.001) lower in the postmenopausal diabetic women (149 +/- 38 micromol/mL/min; n = 47) than values in healthy postmenopausal women (173 +/- 32 micromol/mL/min; n = 51). Serum PON1 activity increased (10%) significantly (P =.009) in diabetic women treated with HRT compared with placebo. A significant (P =.02) interaction between baseline PON1 activity and treatment indicated a greater increase in PON1 activity during HRT in women with lower baseline activities. At baseline, serum PON1 arylesterase activity was correlated significantly with plasma HDL cholesterol levels in diabetic women (r = 0.333, P =.01, n = 47), and the increase in serum PON1 activity was correlated significantly with the change in plasma HDL cholesterol during HRT (r = 0.659, P =.0001, n = 28). These data suggest that serum PON1 activity is abnormally low in postmenopausal women with type 2 diabetes and increases during HRT, particularly in women with lower baseline levels and in those who show a concomitant increase in HDL cholesterol.

Authors+Show Affiliations

Division of Medicine, Department of Medical and Surgical Sciences, University of Otago Medical School, Dunedin, New Zealand.No affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

Clinical Trial
Journal Article
Randomized Controlled Trial
Research Support, Non-U.S. Gov't

Language

eng

PubMed ID

11230785

Citation

Sutherland, W H., et al. "Hormone-replacement Therapy Increases Serum Paraoxonase Arylesterase Activity in Diabetic Postmenopausal Women." Metabolism: Clinical and Experimental, vol. 50, no. 3, 2001, pp. 319-24.
Sutherland WH, Manning PJ, de Jong SA, et al. Hormone-replacement therapy increases serum paraoxonase arylesterase activity in diabetic postmenopausal women. Metabolism. 2001;50(3):319-24.
Sutherland, W. H., Manning, P. J., de Jong, S. A., Allum, A. R., Jones, S. D., & Williams, S. M. (2001). Hormone-replacement therapy increases serum paraoxonase arylesterase activity in diabetic postmenopausal women. Metabolism: Clinical and Experimental, 50(3), 319-24.
Sutherland WH, et al. Hormone-replacement Therapy Increases Serum Paraoxonase Arylesterase Activity in Diabetic Postmenopausal Women. Metabolism. 2001;50(3):319-24. PubMed PMID: 11230785.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Hormone-replacement therapy increases serum paraoxonase arylesterase activity in diabetic postmenopausal women. AU - Sutherland,W H, AU - Manning,P J, AU - de Jong,S A, AU - Allum,A R, AU - Jones,S D, AU - Williams,S M, PY - 2001/3/7/pubmed PY - 2001/4/6/medline PY - 2001/3/7/entrez SP - 319 EP - 24 JF - Metabolism: clinical and experimental JO - Metabolism VL - 50 IS - 3 N2 - The paraoxonase (PON1) enzyme is associated with high-density lipoproteins (HDL) in the blood and is low in patients with type 2 diabetes. Hormone-replacement therapy (HRT) can increase HDL cholesterol levels, but its effect on serum PON1 arylesterase activity is uncertain. The aim of the present study was to determine the effect of 6 months' HRT with conjugated equine estrogen and medroxyprogesterone acetate on serum PON1 arylesterase activity in postmenopausal women with type 2 diabetes. Serum PON1 activity was measured immediately before and at the end of the second arm of a randomized, placebo-controlled, crossover with washout study originally designed to test the effect of HRT on plasma lipids in diabetic postmenopausal women. Baseline serum PON1 arylesterase activity was significantly (P <.001) lower in the postmenopausal diabetic women (149 +/- 38 micromol/mL/min; n = 47) than values in healthy postmenopausal women (173 +/- 32 micromol/mL/min; n = 51). Serum PON1 activity increased (10%) significantly (P =.009) in diabetic women treated with HRT compared with placebo. A significant (P =.02) interaction between baseline PON1 activity and treatment indicated a greater increase in PON1 activity during HRT in women with lower baseline activities. At baseline, serum PON1 arylesterase activity was correlated significantly with plasma HDL cholesterol levels in diabetic women (r = 0.333, P =.01, n = 47), and the increase in serum PON1 activity was correlated significantly with the change in plasma HDL cholesterol during HRT (r = 0.659, P =.0001, n = 28). These data suggest that serum PON1 activity is abnormally low in postmenopausal women with type 2 diabetes and increases during HRT, particularly in women with lower baseline levels and in those who show a concomitant increase in HDL cholesterol. SN - 0026-0495 UR - https://www.unboundmedicine.com/medline/citation/11230785/Hormone_replacement_therapy_increases_serum_paraoxonase_arylesterase_activity_in_diabetic_postmenopausal_women_ L2 - https://linkinghub.elsevier.com/retrieve/pii/S0026-0495(01)23442-8 DB - PRIME DP - Unbound Medicine ER -